Frailty in Older Men with Prostate Cancer: a Look at Characteristics and Screening Tools

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational cohort study will describe demographic, clinical, and frailty characteristics of men aged 65 and older with prostate cancer in the Mid-West region of Ireland. It will evaluate the predictive accuracy of three frailty screening tools (G8, CFS, and PRISMA-7) for identifying those at higher risk of poorer outcomes at baseline, 6 months, and 12 months. The study contextualizes how frailty may affect treatment tolerance, hospitalizations, and quality of life in the setting of varying disease stages and treatment strategies. Enrollment is limited to those able to complete assessments in English during standard research nurse hours, with University of Limerick as lead sponsor and University Hospital Limerick as the site.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* adults aged ≥65 years with a diagnosis of prostate cancer

Exclusion Criteria:

* Neither the patient nor the carer has sufficient proficiency in English sufficiently to complete consent or baseline assessment
* Patients will be excluded if they present outside of research nurse (RN) operational hours( 8am and 5pm Monday - Friday).
* Patients who are acutely unwell and unable to answer the questionnaire will also be excluded.

Where it's running

• University Hospital Limerick
  Limerick, Munster, Ireland Recruiting

Study contacts

• Study coordinator: Niamh Peters
• Email: niamh.peters@hse.ie
• Phone: 0035361482900

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer

  This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.

  Recruiting at 8 sites Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Benidorm, Alicante and 9 other locations · NCT07860528

• Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence

  This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.

  Recruiting Phase 2 University Hospital Tuebingen · Heidelberg, Baden-Wurttemberg and 3 other locations · NCT07860047

• Lutetium-177 Ludotadipep for advanced prostate cancer

  This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.

  Recruiting at 7 sites Phase 3 FutureChem · Gyeonggi-do and 7 other locations · NCT07853209

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.